These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 21722670)

  • 21. Peramivir for the treatment of influenza.
    Shetty AK; Peek LA
    Expert Rev Anti Infect Ther; 2012 Feb; 10(2):123-43. PubMed ID: 22339187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural analysis of the novel influenza A (H7N9) viral Neuraminidase interactions with current approved neuraminidase inhibitors Oseltamivir, Zanamivir, and Peramivir in the presence of mutation R289K.
    Tran-To Su C; Ouyang X; Zheng J; Kwoh CK
    BMC Bioinformatics; 2013; 14 Suppl 16(Suppl 16):S7. PubMed ID: 24564719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs.
    Fujisaki S; Takashita E; Yokoyama M; Taniwaki T; Xu H; Kishida N; Sato H; Tashiro M; Imai M; Odagiri T
    Biochem Biophys Res Commun; 2012 Dec; 429(1-2):51-6. PubMed ID: 23131559
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peramivir: an intravenous neuraminidase inhibitor for the treatment of 2009 H1N1 influenza.
    Mancuso CE; Gabay MP; Steinke LM; Vanosdol SJ
    Ann Pharmacother; 2010; 44(7-8):1240-9. PubMed ID: 20516360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of the influenza virus circulating in the Japanese 2013-2014 season.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2015 Sep; 21(9):634-8. PubMed ID: 26096495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drugs: Lines of defence.
    Palmer R
    Nature; 2011 Dec; 480(7376):S9-10. PubMed ID: 22158299
    [No Abstract]   [Full Text] [Related]  

  • 27. Exploring the cause of oseltamivir resistance against mutant H274Y neuraminidase by molecular simulation approach.
    Karthick V; Shanthi V; Rajasekaran R; Ramanathan K
    Appl Biochem Biotechnol; 2012 May; 167(2):237-49. PubMed ID: 22544690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dynamic behavior of avian influenza A virus neuraminidase subtype H5N1 in complex with oseltamivir, zanamivir, peramivir, and their phosphonate analogues.
    Udommaneethanakit T; Rungrotmongkol T; Bren U; Frecer V; Stanislav M
    J Chem Inf Model; 2009 Oct; 49(10):2323-32. PubMed ID: 19780597
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro passaging of a pandemic H1N1/09 virus selects for viruses with neuraminidase mutations conferring high-level resistance to oseltamivir and peramivir, but not to zanamivir.
    McKimm-Breschkin JL; Rootes C; Mohr PG; Barrett S; Streltsov VA
    J Antimicrob Chemother; 2012 Aug; 67(8):1874-83. PubMed ID: 22563014
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of substitutions in the neuraminidase of A(H7N9) influenza viruses selected following serial passage in the presence of different neuraminidase inhibitors.
    Farrukee R; Butler J; Reading PC; Hurt AC
    Antiviral Res; 2019 Aug; 168():68-75. PubMed ID: 31132385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peramivir susceptibilities of recombinant influenza A and B variants selected with various neuraminidase inhibitors.
    Fage C; Tu V; Carbonneau J; Abed Y; Boivin G
    Antivir Ther; 2017; 22(8):711-716. PubMed ID: 29082897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peramivir Phosphonate Derivatives as Influenza Neuraminidase Inhibitors.
    Wang PC; Fang JM; Tsai KC; Wang SY; Huang WI; Tseng YC; Cheng YS; Cheng TJ; Wong CH
    J Med Chem; 2016 Jun; 59(11):5297-310. PubMed ID: 27167096
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A community cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November to December 2013.
    Takashita E; Ejima M; Itoh R; Miura M; Ohnishi A; Nishimura H; Odagiri T; Tashiro M
    Euro Surveill; 2014 Jan; 19(1):. PubMed ID: 24434172
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance.
    Burnham AJ; Baranovich T; Govorkova EA
    Antiviral Res; 2013 Nov; 100(2):520-34. PubMed ID: 24013000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir.
    Renaud C; Pergam SA; Polyak C; Jain R; Kuypers J; Englund JA; Corey L; Boeckh MJ
    Transpl Infect Dis; 2010 Dec; 12(6):513-7. PubMed ID: 21062390
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, in silico studies, synthesis and in vitro evaluation of oseltamivir derivatives as inhibitors of neuraminidase from influenza A virus H1N1.
    Neri-Bazán RM; García-Machorro J; Méndez-Luna D; Tolentino-López LE; Martínez-Ramos F; Padilla-Martínez II; Aguilar-Faisal L; Soriano-Ursúa MA; Trujillo-Ferrara JG; Fragoso-Vázquez MJ; Barrón BL; Correa-Basurto J
    Eur J Med Chem; 2017 Mar; 128():154-167. PubMed ID: 28182988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-influenza virus activity of peramivir in mice with single intramuscular injection.
    Bantia S; Arnold CS; Parker CD; Upshaw R; Chand P
    Antiviral Res; 2006 Jan; 69(1):39-45. PubMed ID: 16325932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro activity of favipiravir and neuraminidase inhibitor combinations against oseltamivir-sensitive and oseltamivir-resistant pandemic influenza A (H1N1) virus.
    Tarbet EB; Vollmer AH; Hurst BL; Barnard DL; Furuta Y; Smee DF
    Arch Virol; 2014 Jun; 159(6):1279-91. PubMed ID: 24311151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The I427T neuraminidase (NA) substitution, located outside the NA active site of an influenza A(H1N1)pdm09 variant with reduced susceptibility to NA inhibitors, alters NA properties and impairs viral fitness.
    Tu V; Abed Y; Barbeau X; Carbonneau J; Fage C; Lagüe P; Boivin G
    Antiviral Res; 2017 Jan; 137():6-13. PubMed ID: 27838351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic review of influenza resistance to the neuraminidase inhibitors.
    Thorlund K; Awad T; Boivin G; Thabane L
    BMC Infect Dis; 2011 May; 11():134. PubMed ID: 21592407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.